Evaluation of Functionally Meaningful Measures for Clinical Trials of Cognition Enhancement in Schizophrenia

Green, Michael F.; Schooler, Nina R.; Kern, Robert S.; Frese, Fred; Granberry, Wendy; Harvey, Philip D.; Karson, Craig N.; Peters, Nancy; Stewart, Michelle; Seidman, Larry J.; Sonnenberg, John; Stone, William S.; Walling, David; Stover, Ellen; Marder, Stephen R.

doi:10.1176/appi.ajp.2010.10030414

Cited by 149 publications

(138 citation statements)

References 23 publications

Supporting

Mentioning

128

Contrasting

Unclassified

Order By: Relevance

“…A review of literature suggests that the impairments described in relation to schizophrenia are largely homogeneous across different contexts [14,15]. However, a number of environmental, cultural, psychosocial and treatment related factors among others may determine the differences in outcome and the expression of functional impairments in schizophrenia across contexts.…”

Section: Introductionmentioning

confidence: 99%

Assessment of Functioning among Nigerians with Schizophrenia in a Tertiary Health Facility: Influence of Psychopathology, Socio-demographic and Treatment Factors

Campbell

Olagunju

Aina

et al. 2015

J. Psychosoc. Rehabil. Ment. Health

View full text Add to dashboard Cite

To investigate the profile of functional impairment and the influence of psychopathology with other determinants among individuals with schizophrenia in a Nigerian tertiary health facility. The study participants consisted of one hundred adults with schizophrenia. Eligible participants were recruited using systematic random sampling technique. All participants were interviewed with questionnaire to elicit socio-demographic and treatment related information. This was followed by interview with brief psychiatric rating scale (BPRS) and the global assessment of functioning (GAF) to assess for psychopathology and impairment in functioning respectively. Analyses of data were done using SPSS-16. The mean age of the participants was 33.87(±11.6) years and a little above half (52 %) of the participants were female. Sixty (60 %) subjects had active psychopathology using BPRS cut-off score of [10; while participants with duration of illness of more than 10 years (X 2 = 5.59, p = 0.018) and previous relapse (X 2 = 6.34, p = 0.012) were more likely to have psychopathology. Overall, a little over two-thirds (69 %) had impairment following administration of GAF. Mild impairment was observed in 23 % of the participants, moderate impairment in 19 and up to 18 % of participants had severe impairment due to psychopathology. Subjects with lesser education, duration of illness of more than 10 years, extrapyramidal side effects (EPSE), previous relapse and psychopathology had significant levels of impairment (p \ 0.05). However, it was education (Odds ratio [OR] = 0.060; 95 % Confidence interval [95 % CI] = 0.055, 0.770; p = 0.031), psychopathology (OR 5.265; 95 % CI 2.744, 13.626; p \ 0.001) and EPSE (OR 0.183; 95 % CI 0.049, 0.939; p = 0.043) that were independently associated with impairment in functioning following logistic regression to control for effects of confounders. In this study, varied degrees of impairment in functioning were prevalent among individuals with schizophrenia under treatment. However, those with lesser education, EPSE, active psychopathology and longer duration of illness were more likely to be impaired. Thus, better attention to the management of active psychopathology and prevention of extra-pyramidal side effects are indicated in order to promote improve functioning in schizophrenia. In addition, promotion of recovery oriented psychosocial services with need-based rehabilitation program for individuals with schizophrenia is advocated. There is need for more research on predictors of functioning towards promotion of evidence based rehabilitation.

show abstract

Section: Introductionmentioning

confidence: 99%

Assessment of Functioning among Nigerians with Schizophrenia in a Tertiary Health Facility: Influence of Psychopathology, Socio-demographic and Treatment Factors

Campbell

Olagunju

Aina

et al. 2015

J. Psychosoc. Rehabil. Ment. Health

View full text Add to dashboard Cite

show abstract

“…Najnowsze badania nad niedomogą poznawczą wśród osób chorujących na schizofrenię sugerują związek deficytów poznawczych z późniejszym funkcjonowaniem społecz-nym chorych [13,14,15,16].…”

Section: Wstępunclassified

“…Recent research on cognitive deficits among people with schizophrenia suggests a link between cognitive deficits and later social functioning of patients [13,14,15,16].…”

Section: Introductionmentioning

confidence: 99%

Review paper. Neuropsychological dimension of schizophrenia - evaluation possibilities and therapeutic implications

Makarewicz

Karakuła-Juchnowicz

Łobejko

2017

Current Problems of Psychiatry

View full text Add to dashboard Cite

Introduction: In the last decades, researchers' attention has been focused on cognitive dysfunction in schizophrenia. Numerous studies indicate the existence of neurodegenerative deficits in schizophrenia including, but not limited to, motor functions, learning and memory, executive functions, attention, language, spatial skills and general intelligence.Method: A review of available literature on the topic of the past two decades, available in the Pubmed, EBSCO, SCOPUS databases has been made using the keywords: schizophrenia, cognition, early intervention.Results: Cognitive dysfunction is an important feature of the prodromal phase and the first episode of schizophrenia. Researchers have thus proposed to initiate early therapeutic interventions for people with so-called risky mental conditions. The article includes the reference to research on neurocognitive disorders essence in schizophrenia, the definition and review of methods used to identify specific cognitive deficits and issues related to risk of developing psychosis and early therapeutic intervention in high-risk states.Conclusions: Researchers report the importance of detecting cognitive disorders in the early stages of schizophrenia. This broadens the range of therapeutic interventions and enables early intervention in the increased risk of psychosis.

show abstract

“…42 Ultimately, the MATRICS Co-Primary and Translation (MATRICS-CT) consortium launched the Validation of Intermediate Measures (VIM) Study, which selected the UPSA as the leading co-primary measure of functional capacity for use in clinical trials. 43 Performance-based instruments are also being used in the validation process of many new interview-based cognition scales. The UPSA, for instance, was used in construct validation of the Schizophrenia Cognition Rating Scale (SCoRS) 44 and, more recently, in the validation process of the Cognitive Assessment Interview (CAI), alongside the TABS.…”

Section: Functional Capacitymentioning

confidence: 99%

Functional capacity: a new framework for the assessment of everyday functioning in schizophrenia

Mantovani

Teixeira

Salgado

2015

Braz. J. Psychiatry

View full text Add to dashboard Cite

Evaluation of Functionally Meaningful Measures for Clinical Trials of Cognition Enhancement in Schizophrenia

Cited by 149 publications

References 23 publications

Assessment of Functioning among Nigerians with Schizophrenia in a Tertiary Health Facility: Influence of Psychopathology, Socio-demographic and Treatment Factors

Assessment of Functioning among Nigerians with Schizophrenia in a Tertiary Health Facility: Influence of Psychopathology, Socio-demographic and Treatment Factors

Review paper. Neuropsychological dimension of schizophrenia - evaluation possibilities and therapeutic implications

Functional capacity: a new framework for the assessment of everyday functioning in schizophrenia

Contact Info

Product

Resources

About